echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pharmaceutical companies have been positive in consistency evaluation, and a large number of drugs have been evaluated within a week

    Pharmaceutical companies have been positive in consistency evaluation, and a large number of drugs have been evaluated within a week

    • Last Update: 2022-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Under the influence of factors such as the normalization of collection, the continuous deepening of pharmaceutical reform, and the intensification of market competition, pharmaceutical companies are actively promoting the evaluation of
    generic drugs.
    According to the data, as of the end of July this year, the total acceptance number of the consistency evaluation of generic drugs has reached 4112, and 2603 acceptance numbers have been passed, and 2205 have
    been passed.
    In August, 84 new consistency evaluation acceptance numbers were added; 85 approvals (including 62 deemed approved) were evaluated
    .
    It is worth noting that since September, pharmaceutical companies have remained very positive
    in the evaluation.
    It is reported that in the past week, a large number of drugs have been evaluated
    .

     

    On the medicine Xinyi warfarin sodium tablets have been reviewed
     
    On the medicine Xinyi warfarin sodium tablets have been reviewed
    On September 26, Shanghai Pharmaceutical issued an announcement that its holding subsidiary, Shanghai Pharmaceutical Xinyi, received the "Notice of Approval of Drug Supplement Application" issued by the State Food and Drug Administration on warfarin sodium tablets, and the drug passed the consistency evaluation of
    generic drugs.
    Warfarin sodium tablets are mainly used for the prevention and treatment of thromboembolic complications after deep vein thrombosis (DVT) and pulmonary embolism (PE), atrial fibrillation (AF), and/or heart valve replacement to reduce the risk of
    death, recurrence, and thromboembolic events (such as stroke or systemic embolism) after myocardial infarction.

     

    The drug was developed by Bristol-Myers Squibb and was launched
    in the United States in 1954.
    At present, the main manufacturers of the drug in China have Finland Orion Pharmaceutical Factory, Qilu Pharmaceutical Co.
    , Ltd.
    and so on
    .
    It is understood that as of the announcement date, Shanghai Pharmaceutical has invested about 13.
    32 million yuan
    in research and development costs for the consistency evaluation of the drug.

     

     
    Northeast Pharmaceutical levonorgestrel tablets have been reviewed
     
    Northeast Pharmaceutical levonorgestrel tablets have been reviewed
    On September 25, Northeast Pharmaceutical announced that the company recently received the approval notice of drug supplement application for levonorgestrel tablets approved by the State Drug Administration, and the drug passed the consistency evaluation
    of generic quality and efficacy.
    It is understood that the drug is suitable for emergency contraception in women, that is, when
    there is no protective measure or other contraceptive method accidental mistakes.

     

    Northeast Pharmaceutical said that levonorgestrel tablets successfully passed the consistency evaluation and have the qualification conditions to
    participate in the centralized procurement of national drugs.
    This move will help enhance the competitiveness of the product market and accumulate experience
    for the company's follow-up products to carry out generic drug consistency evaluation.

     

    Lisheng Pharmaceutical hydrochlorothiazide tablets have been reviewed
     
    Lisheng Pharmaceutical hydrochlorothiazide tablets have been reviewed
    On September 23, Tianjin Lisheng Pharmaceutical Co.
    , Ltd.
    announced that it recently received the "Notice of Approval of Drug Supplemental Application" (approval number: 2022B03878) issued by the State Drug Administration on the 25mg specification of hydrochlorothiazide tablets (hereinafter referred to as "the drug"), and the drug passed the consistency evaluation
    of generic drug quality and efficacy.

     

    Chinese medicine cefotaxime sodium review
     
    Chinese medicine cefotaxime sodium review
    China Pharmaceutical announced on September 23 that GM Sanyo, a wholly-owned subsidiary of the company, received two copies of the "Notice of Approval of Drug Supplement Application for Drug Supplementation" issued by the State Food and Drug Administration for injection of cefotaxime sodium, which passed the consistency evaluation
    of generic drug quality and efficacy.
    The data show that cefotaxime sodium is a semi-synthetic third-generation cephalosporin antibiotic, which belongs to the β-lactam antibiotic, and has a good antibacterial effect
    on gram-negative bacteria and gram-positive bacteria.
    As of the date of the announcement, the drug consistency evaluation research and development investment was about 5.
    43 million yuan (unaudited
    ).

     

    Yuekang Pharmaceutical Injection Omeprazole sodium has been reviewed
     
    Yuekang Pharmaceutical Injection Omeprazole sodium has been reviewed
    On September 22, Yuekang Pharmaceutical announced that the company recently received the "Notice of Approval of Drug Supplement Application" issued by the State Drug Administration on omeprazole sodium (40mg) for injection, and the drug passed the consistency evaluation
    of generic drug quality and efficacy.
    It is reported that omeprazole can inhibit gastric acid secretion
    by inhibiting the activity of H+-K+-ATPase in gastric parietal cells.
    Omeprazole sodium for injection has been used in clinical practice for more than 20 years, and its clinical application is evidence-based, and it has been recommended as one of
    the preferred drugs for gastrointestinal ulcers by many guidelines or expert consensus at home and abroad.
    The annual sales trend of sample hospitals in China (urban public) in 2021 shows that the sales of omeprazole sodium for injection are 2.
    484 billion yuan
    .

     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.